|
|
The Heart Drug Launch That Could Deliver 95% Upside From Here |
|
|
A cardiac drug launched late last year is scaling faster than the Street modeled, and one mid-cap biotech is carrying the whole story. |
A top-ranked analyst just reiterated a target roughly 95% above where the stock trades today, with the next launch update only two weeks out. |
|
|
|
|
Free Report (Sponsored) |
|
|
|
A company doesn’t raise its dividend for 50+ years by accident. |
It takes durability, discipline — and a business built to survive anything. |
Our latest report reveals 7 “buy and hold forever” stocks with decades-long payout histories and rock-solid balance sheets. |
One healthcare leader has increased its dividend for 61 consecutive years. |
These are the types of companies designed to quietly compound wealth over time. |
Download your free copy now.
(By clicking the link above, you agree to receive emails from Marketbeat. You can opt out at any time. - Privacy Policy) |
|
|
|
|
BridgeBio Pharma |
|
|
August 3 – Pre‑market
Ticker: BBIO | Sector: Healthcare (Biotech) | Market Cap: ~$15-16B |
|
|
|
|
30‑Second Take |
Why now? BridgeBio launched Attruby, its ATTR-cardiomyopathy drug, late last year. The ramp is what's driving this story. |
Wall Street is looking for revenue to nearly double this year to around $960 million, with another leg higher in 2027 as scripts scale. |
Cantor Fitzgerald's Louise Chen just reiterated her overweight rating with a $157 price target. That's roughly 95% upside from where BBIO trades today. |
This isn't a hype trade. It's a real drug, a real market (ATTR-CM is a $10B-plus opportunity), and a real launch you can track quarter by quarter. |
|
|
Trade Setup |
Time frame: 6 to 12 months
Edge type: Post-launch catalyst ramp with analyst PT expansion |
You're not betting on a binary FDA decision here. That part's done. |
What you're betting on is the Attruby launch trajectory beating conservative Street models, and driving upward revisions to revenue and EPS over the next 2 to 3 quarters. |
The setup is a classic mid-cap biotech transition. Cash-burning developer flips to commercial-stage cash generator. When that flip happens cleanly, the multiple re-rates hard. |
Add in a competitor label (Pfizer's tafamidis) that Attruby's clinical data may outperform, and you have a story that could work even if the broader market stalls. |
|
|
Early Moves (Sponsored) |
|
|
|
Most market moves only get attention once they’re already underway. |
The earliest phases tend to be quieter — showing up as subtle structural shifts, not headlines. |
Right now, a handful of small-cap names across AI, energy, and emerging tech are starting to display those same early characteristics. |
We’ve outlined three examples — and what we’re watching next. |
View the report.
(By clicking the link above, you agree to receive emails from FierceInvestor. You can opt out at any time. - Privacy Policy) |
|
|
|
|
Poll: Looking back at your investing year so far, what would you most change? |
|
|
|
|
Snapshot Table |
Metric |
Value |
Current Stance |
Price |
$79.96 |
Well below Cantor's $157 PT |
52‑week range |
$42.09 to $93.42 |
Mid-range, roughly 14% below the high |
Market Cap |
~$15-16B |
Mid-cap sweet spot |
P/E Ratio |
N/A (not yet profitable) |
Valuation on revenue and pipeline |
Avg Daily Volume |
~3.1M shares (3-month avg) |
Liquid enough for position sizing |
Next Catalyst |
Q2 earnings and Attruby launch update, expected mid-August |
Within 2 weeks |
|
|
|
Chart |
|
|
1-Month Trading Summary: BBIO has been base-building ahead of the Q2 update, with Attruby script data providing the fundamental support. |
Watch for volume expansion on any close above recent resistance. That's often the first tell that institutions are positioning ahead of the launch numbers. |
|
|
Bull Case |
Core thesis: BBIO isn't a will-the-drug-work story anymore. Attruby (acoramidis) is approved, launched, and generating revenue right now. |
The bull case is simple. The launch is going better than the Street modeled, and the numbers are about to prove it. |
Catalysts: The ATTR-CM market itself is the tailwind. Transthyretin amyloid cardiomyopathy is dramatically underdiagnosed, and as cardiologists learn to look for it, the treatable patient population keeps expanding. |
Pfizer's tafamidis (Vyndaqel/Vyndamax) built a multi-billion-dollar franchise on this exact dynamic. Attruby is now the second entrant, and its ATTRibute-CM trial data on all-cause mortality gave it a differentiated marketing angle. |
Valuation upside: Chen isn't a random bull. She's one of the most-followed biotech analysts on the Street, and her $157 target is a real number, not a moonshot. |
If she's right and revenue doubles to $960M this year with another sharp step-up in 2027, the current market cap looks like a bargain on standard commercial-stage biotech multiples. |
Then there's the pipeline. Attruby is the anchor, but BBIO still has multiple mid- and late-stage programs, giving you optionality on top of the core thesis. |
What I like most is that the catalyst path is dense and specific. Q2 earnings and launch update in mid-August. Then Q3 in November. Every 90 days, you get a fresh print to reprice against. |
|
|
Bear Case |
Now the risks, because you need to know what could blow this up. |
Launch execution risk is real. Every launch story looks great until it doesn't. If Attruby scripts come in soft in Q2, the stock gets hit hard, analyst targets get cut, and the re-rating thesis stalls. |
Post-launch biotechs live and die on the trajectory of the first four quarters. |
Then there's competitive pressure. Pfizer's tafamidis has years of physician relationships and payer contracts already locked in. Attruby has to displace an entrenched incumbent, and that takes time. Alnylam's vutrisiran is also in the mix. |
Biotech multiples are volatile too. If the sector rolls over on macro (rate expectations, risk-off), BBIO gets caught up in it regardless of company-specific news. |
Finally, the balance sheet. BBIO burned cash for years to get here. Even with Attruby revenue ramping, you'll want to see the cash runway extending, not shrinking. |
If you're going to own it, size it accordingly. This is a mid-cap biotech, not a utility. |
|
|
Quick Checklist |
✅ Thesis still valid after today's close
✅ Volume confirms move above key levels
✅ Q2 earnings and Attruby launch update confirmed for mid-August |
|
|
Deep‑Dive Links |
|
|
|
|
That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned! |
Best Regards,
—Noah Zelvis
Everyday Alpha |
0 التعليقات:
إرسال تعليق